Great appointment - and also here's a snippet for holders who...

Great appointment - and also here's a snippet for holders who are looking for some financial guidance in the form of firm projected outputs from the new boards strategies : For  CellLive2:

"With the CellLive2 product development now embedded in the 2nd generation product, Optiscan is now ready to take this new product to market through direct and indirect channels over the coming 12 months.

After completion of the final stages of preparing the CellLive2 for commercialisation, we anticipate sales to commence late in 2016. We estimate sales to build to levels in excess of $1.4m in the 2016/2017 Financial Year. Furthermore, building on the 2016/17 sales momentum, we anticipate sales revenues to be generated into 2017/18 at levels that will ensure Optiscan is cash flow positive from that point forward".